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Abstract: The different kinds of bone-conduction devices (BCDs) available for hearing 
rehabilitation are growing. In this paper, all BCDs currently available or in clinical trials will 
be described in categories according to their principles. BCDs that vibrate the bone via the 
skin are referred to as skin-drive devices, and are divided into conventional devices, which are 
attached with softbands, for example, and passive transcutaneous devices, which have implanted 
magnets. BCDs that directly stimulate the bone are referred to as direct-drive devices, and are 
further divided into percutaneous and active transcutaneous devices; the latter have implanted 
transducers directly stimulating the bone under intact skin. The percutaneous direct-drive device 
is known as a bone-anchored hearing aid, which is the BCD that has the largest part of the market 
today. Because of some issues associated with the percutaneous implant, and to some extent 
because of esthetics, more transcutaneous solutions with intact skin are being developed today, 
both in the skin-drive and in the direct-drive category. Challenges in developing transcutaneous 
BCDs are mostly to do with power, attachment, invasiveness, and magnetic resonance imaging 
compatibility. In the future, the authors assume that the existing percutaneous direct-drive BCD 
will be retained as an important rehabilitation alternative, while the transcutaneous solutions 
will increase their part of the market, especially for patients with bone-conduction thresholds 
better than 35 dB HL (hearing level). Furthermore, the active transcutaneous direct-drive BCDs 
appear to be the most promising systems, but to establish more detailed inclusion criteria, and 
potential benefits and drawbacks, more extensive clinical studies are needed.
Keywords: bone-conduction device, implantable, transcutaneous, percutaneous, active, 
passive
Introduction
Bone-conduction devices (BCDs) are used in a wide range of applications such as 
communication systems, language development approaches, mitigation of stuttering, 
audiometric investigations and finally and most importantly, in hearing rehabilitation. 
This review is focused on BCDs for hearing rehabilitation, where the common indi-
cations are conductive and mixed hearing loss and also single-sided deafness. These 
BCD devices can be non-implantable (conventional BCDs) and semi-implantable, 
where some part of the device is implanted. In what follows, the term implanted is 
used instead of semi-implanted for simplicity, as fully implanted BCDs (all parts 
implanted) are most likely just hypothetical and hard to implement due to the huge 
inherent vibration feedback problems.
Conventional BCDs were developed in the beginning of the 20th century1,2 with a 
sound processor attached with spectacles, steel spring headbands, or soft headbands. 
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The vibrations that are produced are transmitted through the 
skin to the skull bone, and further to the cochlea in the inner 
ear, bypassing a conductive impairment in the external or 
middle ear. The development of the conventional BCD was 
a big step forward in the rehabilitation of these patients; 
however, the devices have some drawbacks. The static 
pressure on the skin needs to be high enough to transmit 
the vibrations to the cochlea, leaving the skin compressed, 
which might lead to discomfort and skin problems in the 
attachment area. The primary issue with conventional BCDs, 
applied with a headband as well as with frames of a pair of 
glasses, is related to the static pressure of approximately 
2 N towards the skin and the soft tissues.3 Furthermore, the 
skin attenuates the high-frequency vibrations, and therefore, 
the sound that reaches the cochlea has a lower content of 
high frequencies.
In the 1960s, Per-Ingvar Brånemark discovered that 
bone can attach firmly on titanium (ie, titanium can be 
osseointegrated).4 This discovery was first used in dental 
implants with great success. In the late 1970s, a project 
started as a collaboration between Chalmers University of 
Technology, Sahlgrenska University Hospital, and Brånemark 
Osseointegration Center to develop a hearing aid attached to 
an integrated screw in the skull bone.5 This new percutaneous 
BCD was called the bone-anchored hearing aid (BAHA), and 
had several advantages over the conventional BCD. Most 
importantly, the skin was not compressed, eliminating the 
circulatory problems, and furthermore, when vibrations were 
transmitted through the screw directly to the bone instead of 
through the skin, the high frequencies were also preserved. 
This device has been improved over the years, and today (in 
2014) more than 150,000 patients have been treated.6,7 The 
BAHA offers good hearing rehabilitation, but still there are 
some drawbacks associated with the skin-penetrating implant 
(eg, loss of osseointegration, and skin complications).8–13 The 
esthetical appearance is also a debated issue, although not 
scientifically assessed.
The success with the BAHA initiated new ideas of 
implantable BCDs which did not need a percutaneous 
implant. Instead implantable BCDs transmitted the signal 
transcutaneously using different techniques. Already in the 
1980s, the Audiant Xomed was developed by Jack Hough 
et al.14 This device used an implanted magnet anchored in the 
temporal bone under the skin behind the ear. The Xomed’s 
external audio processor included a magnet that was attracted 
to the implanted magnet. The implanted magnet was not only 
used for retention, the magnet was also part of the vibration 
transducer design, and thus the vibrations were directly 
transmitted to the skull bone. However, the problem with 
this transducer design was that the skin formed the required 
air gap in the transducer (air gap of size 4–5 mm due to skin 
thickness), which gave an output that was approximately 
20 dB lower than the BAHA (air gap of approximately 
0.1 mm).15 Because of the power issues related to large air 
gaps and because of skin complications related to skin com-
pression, the Xomed device was withdrawn from the market 
after a couple of years.
Following the Xomed failure, there was no interest in 
transcutaneous implantable BCDs for many years, but during 
the last 10 years, several new projects have evolved with the 
purpose to develop transcutaneous implantable solutions. 
The driving forces behind this trend are to find solutions that 
are more esthetically appealing, and maybe most importantly, 
to avoid the challenges associated with permanent skin pen-
etration used in BAHA systems. Some of the new devices 
are already on the market, while others are in clinical trials. 
The implantable BCDs can be divided into two main groups: 
first, “direct-drive systems” (Baha®, Ponto, bone-conduction 
implant [BCI], and Bonebridge™), where the vibrations are 
transmitted directly to the skull bone; and secondly, “skin-
drive systems,” where the vibrations are transmitted through 
the skin (Sophono® and Baha® Attract).
Aim of study
In this paper, all present BCDs for hearing rehabilitation, 
known to the authors to be available on the market or being 
in clinical trials, will be described. The authors have orga-
nized all BCDs into categories to increase the understanding 
of their principles. Middle-ear implants and direct acoustic 
cochlear implants do not use BC and are therefore excluded 
from this review.
Bone-conduction devices
To categorize all existing BCDs for hearing rehabilitation, the 
first division was made into “direct-drive” BCDs and “skin-
drive” BCDs (see Figure 1). All direct-drive BCDs transmit 
vibrations directly to the skull bone, not through the skin. 
Skin-drive BCDs transmit vibrations through the skin, and 
can be divided into conventional and passive transcutane-
ous BCDs. A similar division could be made to direct-drive 
BCDs, which are divided into percutaneous and active tran-
scutaneous devices. There is also a category of BCDs called 
in-the-mouth devices, which are neither direct-drive nor 
skin-drive BCDs, as they stimulate the ear by transmitting 
vibrations via a tooth and its relatively stiff root connected 
to the skull.
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This chapter describes all BCDs that are on the market 
and those that are approaching the market in clinical trials. 
More technical details of the transducer designs in these 
generic BCDs are presented by Håkansson.16
Skin-drive BCDs
All skin-drive BCDs are characterized by the fact that the 
vibrations are transmitted through the skin, which is kept 
intact. In conventional skin-drive BCDs, all components 
are kept outside the skin, while the passive transcutaneous 
skin-drive BCDs contain implanted magnet(s).
Conventional skin-drive BCD
The conventional skin-drive BCD was the first BCD on the 
market (see Figure 2). It is attached with a soft headband 
(softband), a steel spring headband, or with spectacles for 
glasses. Today there are a few companies that still manufac-
ture and offer conventional devices – for example, BHM-Tech 
in Austria and Bruckhoff in Germany. In addition, BAHAs 
are sometimes used with a softband/headband instead of a 
titanium screw, thus behaving as a conventional skin-drive 
device. There are two manufacturers of BAHAs, Oticon 
Medical (Askim, Sweden) and Cochlear Bone Anchored 
Solutions (Mölnlycke, Sweden), where the BAHAs are also 
available with softband/headband application.
The use of BAHA on a softband (elastic fabric) or 
headband (diadem type) is a valuable method of hearing 
rehabilitation in children who are too young for implanta-
tion,17,18 and it is the gold standard for preoperative assess-
ment.19 However, one should bear in mind that the final 
hearing improvement with a percutaneous BAHA usually 
is  better than with a BAHA on a softband.20,21 In particular, 
Verstraeten et al22 have shown that the hearing sensitivity 
through the skin, as compared with a skin penetrating abut-
ment, is between 8 and 20 dB lower in the frequency range 
from 1 to 4 kHz (see Figure 3 in Verstraeten et al22). This is in 
line with results presented already in the 1980s by Håkansson 
et al,23 who compared the hearing thresholds using the same 
transducer attached first to a percutaneous implant and then 
to the nearby skin.
Furthermore, conventional BC is today used in communi-
cation systems of various kinds. One interesting application 
is the Google Glass24 that uses a BC transducer as a comple-
mentary speaker to air-conduction (AC) receivers.
Bone-conduction devices
Direct-drive
Baha® BonebridgeTM SoundBiteTM Sophono® Baha® AttractPonto BCI
Percutaneous
BAHA
Conventional 
Headband or eyeglasses
Passive transcutaneous
Implanted magnet
Active transcutaneous
Implanted transducer
Skin-driveIn-the-mouth
Figure 1 Categorization of bone-conduction devices.
Abbreviations: BAHA, bone-anchored hearing aid; BCi, bone-conduction implant.
Figure 2 Conventional skin-drive bone-conduction devices, attached with (A) a 
steel spring headband, and (B) with frames for glasses. 
Note: images provided courtesy of (A) Starkey Hearing Technologies, (B) bruckhoff 
hannover gmbh.
Figure 3 Sophono®, a passive transcutaneous skin-drive bone-conduction device.
Note: image provided courtesy of Sophono®.
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There are some generic issues from the conventional skin-
drive BCD related to the skin. First, since the vibrations pass 
through the skin, the static pressure must be high enough to 
provide the best transmission possible. A typical pressure is at 
least 2 N,3 which most often gives discomfort and problems in 
the skin and subcutaneous tissues between the transducer and 
the bone if used long-term. The high static pressure can also 
give tension headaches. Another drawback of transmitting the 
vibrations through the soft skin to the bone is that the vibrations 
get attenuated. This mainly affects the sound at frequencies 
above 1 kHz, which are important for speech reception. A third 
issue relates to feedback, where sound is radiated from the 
transducer back to the microphone. In early versions of the con-
ventional skin-drive BCD, the microphone was placed on the 
other side of the head from the transducer in order to reduce 
the feedback, but it can also be placed in a separate casing on 
the same side of the head, as is shown in Figure 2.
Passive transcutaneous skin-drive BCDs
Passive transcutaneous skin-drive BCDs have appeared on the 
market during the last few years and are available by Sophono® 
(Boulder, CO, USA [originally Otomag, Melle, Germany]) and 
Baha® Attract (Cochlear Bone Anchored Solutions AB).
Sophono® device
The Sophono® device was first presented by Siegert25 under 
the name Otomag system. It uses a retention magnet system 
where two magnets are implanted in the temporal bone, and 
fixated by five small titanium screws, and the sound processor 
is attached on the outside of the skin by magnetic attraction 
force (see Figure 3). The vibrations of the transducer are 
transmitted through the soft tissues, and the skin is most often 
thinned to 4–5 mm thickness (only in adults).26,27 In order to 
overcome skin problems related to high skin pressure, the 
Sophono® Alpha 1 uses a larger contact area than is used in 
conventional BCDs. In this way, the static force is distributed 
over a larger area, which alleviates the skin compression 
that might lead to circulatory problems. The company states 
that this larger area is also “impedance matched” in order to 
enhance the vibration transmission to the cochlea, but so far, 
no scientific papers are available verifying this effect.
In what follows, several clinical studies are presented, 
highlighting the most important results. A summary of audio-
metric results from studies, which are comparable in terms of 
how they have been measured, are found in Table 1. 
Siegert and Kanderske27 made a retrospective study by 
inviting patients who had congenital atresia and who had 
been previously operated on (more than 100 patients since 
2006). Twenty patients showed up, and it was found that they 
improved over the unaided condition by 28.6 dB in pure-tone 
average (PTA) and 61.6% in speech-recognition score (SRS). 
No complications were reported from surgery, but some 
patients reported that they had slight pressure irritation of the 
skin between the implants and the external base plate which 
healed after careful shimming and slight force reduction of 
the base plates.27
Table 1 Summary of audiometric data of implantable bone conduction devices in clinical studies, only including studies that are 
reasonably comparable
Model Type No of 
subjects
PTAbc  
[dB HL]
Ages  
[years]
Etiology Aided vs unaided sound 
field improvement
Reference
PTA4  
[dB HL]
SRT  
[dB HL]
SRS 
[%]
Bonebridge Active trans 12 5–35 19–69 Cond, mixed 25 N/A 78,8 Sprinzl et al59
4 24–36 45–63 Cond, mixed 36,5 36,25 N/A Barbara et al60
6 Average 26 40–57 Cond, mixed 34,9* N/A 80,0* ihler et al62
23 5–60 6–80 Cond, mixed, SSD 29‡ N/A 49 Riss et al63
BCi Active trans 6 0–30 18–67 Cond, mixed 31,0 27,0 51,2† Reinfeldt et al50
Sophono Passive  
trans
20 of .100 Average 11 6–50 Cond 28,6 N/A 61,6 Siegert and 
Kanderske27
6 0–11 5–11 Cond 22* 28* 61* Hol et al28
10 18–36 16–67 Cond, mixed 29,7* 34,1* 84,1* Magliulo et al31
Baha Attract Passive trans 9 of 12 3–26 5–65 Cond 19 19 N/A Işeri et al33
BAHA HC 200 Per 110–122 -1–45 Average 54 Cond, mixed 29,4 26,5 41,6† Tjellström and 
Håkansson35
Notes: *Unaided measured with headphones; †SRS was measured with competing noise, signal-to-noise ratio =4 dB; ‡average of 0.5, 1, 2, 3, 4, and 6 kHz.
Abbreviations: BAHA, bone-anchored hearing aid; BCi, bone-conduction implant; cond, conductive; HL, hearing level; N/A, not applicable; per, percutaneous; PTA4, four-
frequency averages of pure-tone audiometry; PTAbc, pure-tone average for bone-conduction; SRS, speech-recognition score; SRT, speech-recognition thresholds; SSD, single-
sided deafness; trans, transcutaneous.
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The Sophono® has been used on both children and adults, 
and in a comparative study between the Sophono® Alpha 1 
and the percutaneous BAHA (six children with each device) 
by Hol et al,28 the conclusion was that the BAHA-based 
outcome was slightly better in sound-field tone thresholds, 
speech-recognition thresholds (SRT) and SRS at 65 dB SPL 
(sound pressure level) without noise. Hol et al28 also stated 
that the Sophono® offers appealing clinical benefits with no 
adverse skin reactions or implant losses. In the subgroup of 
six children using the Sophono® Alpha 1, the improvement 
over the unaided condition was 22 dB in four-frequency 
PTA (PTA
4
) (average over 0.5, 1, 2, and 4 kHz); 28 dB in 
SRT, and 61% in SRS when no noise was added. It should 
be noted that the unaided condition here was measured with 
headphones and not in a sound field, which might affect the 
comparison, as measurements in a sound field might improve 
the unaided thresholds. For example, consider the situation 
where the patients have large air–bone gaps (ABGs) (range 
of 40–60 dB and below), then the free-field sound may pass 
through the skin and skull, as so-called “body conduction” 
that can be heard at lower levels than via AC through the 
ear canal.29
Sylvester et al30 investigated Sophono® Alpha 1 in 
18 patients with different types of hearing impairments. They 
found that the best improvements were obtained for patients 
with bilateral conductive hearing loss, with an average func-
tional gain of 21.9±10.4 dB, but only minor improvement for 
bilateral mixed loss, with an average gain of 6.2±5.3 dB.30
Magliulo et al31 showed that for their ten Sophono® 
patients with subtotal petrosectomy, the average difference 
between aided sound-field PTA and preoperative AC PTA 
was 29.7 dB. They also got significant improvement in SRT 
of 34.1 dB and in SRS in quiet by 84.1% when comparing 
preoperative unaided values with headphones with aided 
sound-field values, where the contralateral ear was plugged 
and covered with an ear muff.31
A recent paper by O’Niel et al32 reported similar 
audiometric results for the Sophono® device as in the other 
studies but using a slightly different protocol, where in 
unaided condition the contralateral ear was masked and in 
the aided sound-field condition the contralateral ear was 
occluded. This different procedure for the contralateral ear 
might have affected the results. In this study, they stated 
that 5 out of 14 ears (36%) had problems following fitting 
“including swelling, irritation, infection, or significant 
decreased ability to use the device from pain or skin changes.” 
They have some recommendations to overcome these skin 
problems: decreased magnet strength at the initial fitting, 
a graduated wearing schedule, caution with patients who have 
a history of skin issues from a BAHA or multiple surgical 
procedures, and parent counseling regarding potential skin 
irritation in children.32 
It seems that most of the other studies have noted skin prob-
lems in some of the patients and have managed them successfully 
in a similar way.
Baha® Attract device
Baha® Attract got the CE mark and was cleared by the Food 
and Drug Administration at end of 2013, and has since then 
been available on the EU and US markets. The magnet on the 
inside of the intact skin is attached to the skull bone with a 
screw, and the Baha® sound processor is attached to a magnet 
plate on the skin via a soft pad to equalize the force distribu-
tion over the attachment surface (see Figure 4). A multicenter 
clinical study, based on 27 patients, is completed and a pub-
lication is expected in the near future (noted from Cochlear 
Media Release, and the results were orally presented in the 
29th Politzer meeting in Antalya, Turkey, 2013). The first 
available publication is not from this initial study, but instead 
Figure 4 Baha® Attract, a passive transcutaneous skin-drive bone-conduction device.
Note: image provided courtesy of Cochlear Bone Anchored Solutions AB.
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describes the first experience in Turkey on 12 Baha® Attract 
patients.33 They reported that bone smoothing (five patients) 
and soft-tissue reduction (four patients) was needed in some 
of the patients. No postoperative complications were reported, 
except that one patient had skin erythema which was solved 
by decreasing the magnet strength. In the audiometric 
investigation based on nine of the patients, they found an 
improvement in free-field PTA
4
 of 19 dB and in free-field SRT 
of 19 dB.33 Another recently published study by Kurz et al34 
investigated the speech understanding of the Baha® Attract 
by adding artificial skin and the external parts of the Baha® 
Attract system to a magnet on the abutment of 16 BAHA 
users. The contralateral ear was plugged and covered with an 
ear-muff for all sound-field measurements. They found that 
the transmission path through the artificial skin as expected 
gave a lower sensitivity, measured by “BC Direct” (which is 
a built-in feature of the sound processor that measures the 
electrical voltage directly fed to the transducer) for frequen-
cies from 1 kHz and above. However, only smaller differences 
in aided speech understanding between the transmission paths 
were found, which indicates that this lower sensitivity through 
the skin could at least partly be compensated for by adequate 
fitting (higher gain) in the speech processor.34
Direct-drive BCDs
In direct-drive BCDs, the vibrations are transmitted directly 
to the bone via a screw or a flat surface attachment. The 
direct-drive BCDs are mainly divided into percutaneous 
and active transcutaneous devices. It has been debated 
whether the implantable devices are active or passive. This 
classification has been based on definitions in regulatory 
directives in the EU and in the USA rather than on engi-
neering  principles. Thus, a BAHA is regarded as a passive 
device (Class IIb in EU), whereas a device with implanted 
transducer is regarded as an active device (AIMD in the EU 
and Class III in USA).
Percutaneous direct-drive BCD
The BAHA was the first available direct-drive BCD. It was 
developed to mitigate the drawbacks with the conventional 
device (ie, to improve rehabilitation in terms of better high-
frequency sound transmission, and to avoid skin compression 
issues). In the BAHA, the sound processor is attached to the 
skull bone via an abutment to a titanium screw (see Figure 5). 
Hence, in the BAHA, the bone is directly stimulated without 
transmitting the vibrations through the skin.
There are two companies that manufacture BAHAs: 
Cochlear Bone Anchored Solutions AB and Oticon  Medical. 
There have been major improvements of BAHA audio 
processors over the years. Cochlear Bone Anchored Solu-
tions’s most recent models are Baha® 3 Power and Baha® 4. 
Oticon  Medical’s most recent models are in the new Ponto 
Plus family. The models have different inclusion criteria 
regarding the sensorineural hearing component, and have 
been investigated in several studies. BAHAs are mainly 
indicated for conductive and mixed hearing loss as well as 
for single-sided deafness (SSD), and are used both on adults 
and on children.
Among the first results for percutaneous BAHA, Tjellström 
and Håkansson35 included approximately 120 patients with 
the HC 200 device. The improvements with the HC 200 over 
unaided condition was PTA
4
 =29.4 dB, SRT =26.5 dB, and 
SRS =41.6%.35 There are many recent studies with newer 
BAHA models, which have higher  output capability, improved 
transducer technology, and better  fitting procedure, but this 
original study follows essentially the same protocol as the stud-
ies presented here regarding other implantable BCDs, which 
facilitates comparison. By adopting more advanced  signal 
Figure 5 Bone-anchored hearing aid, a percutaneous direct-drive bone-conduction device.
Notes: (A) Ponto (Oticon Medical, Askim, Sweden); and (B) Baha® BP100 (Cochlear Bone Anchored Solutions AB, Mölnlycke, Sweden). images provided courtesy of Oticon 
Medical (A) and Cochlear Bone Anchored Solutions AB (B).
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processing into the BAHA devices, speech  understanding 
when noise comes from the rear is improved.36–38
BAHA has been a huge success with more than 
150,000 users6,7 and offers good hearing rehabilitation and 
is probably the most powerful BCD device today. Despite 
impressive audiometric results, the BAHA has some short-
comings. The skin around the abutment needs life-long 
daily care, and skin complications, such as skin irrita-
tion, skin infections, and skin growing over the abutment, 
occur.8–13 The screw might come loose,8,39 either spontane-
ously or as a result of trauma. Although not scientifically 
investigated, some patients also reject a BAHA because 
of esthetic reasons. There have been several developments 
during recent years regarding the screw implant surface and 
shape,40–42 and surgical technique,43–46 that have improved the 
situation regarding some of the complications. However, the 
fact remains that the implant is still percutaneous.
Active transcutaneous direct-drive BCD
In active transcutaneous direct-drive BCDs, the transducer 
is implanted under intact skin. Hence, the vibrations are 
transmitted from the transducer directly to the skull bone. 
The reason for calling it transcutaneous is that the electro-
magnetic signal from the sound processor is transmitted 
through the skin, not the vibrations. The sound processor is 
attached to the skin by retention magnets in the implanted 
unit, and the sound signal is transmitted via an inductive link 
to the implanted transducer. See Figure 6 for the BCI and 
Figure 7 for the Bonebridge™ from MED-EL (Innsbruck, 
Austria).
The BCI and the Bonebridge™ use similar inductive 
links47 and retention magnet systems, and the main difference 
between these devices is the transducer, and the BCI uses 
the balanced electromagnetic separation transducer (BEST) 
principle48 with a high-frequency boost. By using the BEST 
principle, the BCI transducer is smaller and has lower dis-
tortion and higher efficiency compared with the transducer 
that is used in BAHAs.48 The BCI transducer casing has 
a rectangular shape with rounded corners, and the size is 
approximately 14 mm ×12 mm ×7.4 mm. The Bonebridge™ 
uses a floating mass transducer that has a cylindrical shape 
with diameter 15.8 mm and height 8.7 mm.
Table 2 MPO and reference thresholds for implantable BCDs
Device MPO in force level [dB re 1μN] Comment/reference
0.5 k 1 k 2 k 4 k PTA4
1.  Bonebridge MPO @ Skullsimulator 93 104 102* 84 95.8 Håkansson B, personal 
communication, 2014
2. BCi MPO @ Skullsimulator 97 102 94* 95 97.0 Taghavi et al, 
unpublished data, 2014
3.  RETFL DBC @ pos A (BAHA) 48 45.5 26 27.5 36.8 Carlsson and 
Håkansson79
4.  Correction: Pos A (BAHA) vs pos B (BCi) [dB] 3 9 10 8 7.5 Reinfeldt et al50
5.  RETFL DBC @ pos B (BCi) 45 36.5 16 19.5 29.3 Calculated (3 minus 4)
Notes: Pos A refers to the approximate skull position for a BAHA, 55 mm behind and slightly above the ear-canal opening. Pos B is the skull position for the BCi, 10–15 mm 
behind the ear-canal opening. Correction (4) is the calculation of the sensitivity difference between stimulation of the BCi and the BAHA positions (pos B and pos A, 
respectively). @, attached to. *values were taken slightly below 2 kHz to avoid interference with a resonance peak.
Abbreviations: BAHA, bone-anchored hearing aid; BCi, bone-conduction implant; BCD, bone-conduction device; DBC, direct bone conduction; MPO, maximum power 
output; pos A, position A; pos B, position B; PTA4, four-frequency pure-tone average; re, relative to; RETFL, reference equivalent threshold force level. 
Table 3 Maximum dynamic ranges and suggested BC thresholds for implantable BC devices
Device Max dynamic range with normal  
cochlear function [dB HL]
Comment/ 
reference
Max PTAbc at aided 
PTA =30–35 dB HL
0.5 k 1 k 2 k 4 k PTA4
Bonebridge Alt 1 48 68 86 65 67 Calculated* 32–37
Bonebridge Alt 2 55 61 71 60 62 Mertens et al73 27–32
BCi 52 66 78 76 68 Calculated** 33–38
Sophono @ Skullsimulator 51 53 64 50 54 Zwartenkot70 19–24
Baha Divino @ Skullsimulator 64 68 75 68 69 Zwartenkot70 34–39
Baha Cordelle @ Skullsimulator 80 75 87 81 81 Zwartenkot70 46–51
Notes: Dynamic range is calculated from Table 2 and from published MPO dB HL data. indication range in PTA4 BC, assuming aided PTA4 of 30–35 dB HL, is calculated as 
the dynamic range minus 30–35 dB. *Row 1 minus row 5 in Table 2; **row 2 minus row 5 in Table 2. @, attached to.
Abbreviations: Alt, alternative; BC, bone-conduction; BCi, bone-conduction implant; HL, hearing level; max, maximum; MPO, maximum power output; PTA, pure-tone 
average; PTA4, four-frequency pure-tone average; PTAbc, pure-tone average for bone-conduction.
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The BCI system was developed in collaboration between 
Chalmers University of Technology and Sahlgrenska 
University Hospital in Gothenburg, Sweden. The clinical 
study on 20 patients is ongoing, and so far, six patients 
have received the implant. The audiometric results of the 
first patient at the 1-month follow-up are published by Eeg-
Olofsson et al49 and the first six patients’ 6-month follow-up 
by  Reinfeldt et al.50 Before the clinical study, preclinical stud-
ies were performed on cadavers,51–54 dry skulls,55 animals,56,57 
and normal-hearing subjects.58 In the important preclinical 
studies on the cadavers,51,52 where it was first concluded that 
an active transcutaneous BCD could be a realistic alternative 
to a percutaneous system, the sound processor and induction 
link from the Vibrant Soundbridge (the study was supported 
by MED-EL) was used to drive a BEST transducer. One 
important finding in these investigations was that MPO in the 
transcutaneous solution was considered high enough com-
pared with a percutaneous BAHA solution, which most likely 
triggered the work to develop complete active transcutaneous 
systems like the BCI and the Bonebridge™ systems.
Reinfeldt et al50 showed that the improvement from 
unaided to aided PTA
4
 for the first six patients using the BCI 
was 31.0±8.0 dB. The SRT improvement was 27.0±7.6 dB, 
the SRS improvement was 51.2%±8.9%, while the signal-to-
noise ratio threshold for the BCI was -5.5±2.3 dB. Also, the 
questionnaires APHAB (Abbreviated Profile of Hearing Aid 
Benefit) and GBI (Glasgow Benefit Inventory) showed sig-
nificant improvement in quality of life for the patients using 
the BCI. Furthermore, it was found that the BCI results were 
better or similar compared with the results of a BAHA (Ponto 
Pro Power) on a softband, which was used for 1 month prior 
to the BCI surgery. It was concluded in the study that the 
BCI gives significant hearing rehabilitation for patients with 
mild-to-moderate conductive or mixed hearing loss, and that 
the surgical procedure is safe and uncomplicated.50
The Bonebridge™ was developed by MED-EL and has 
been on the market since spring 2012, indicated for patients 
with conductive and mixed hearing loss, and SSD. Since 2014, 
it has also been approved for children from 5 years of age. 
Sprinzl et al59 operated on 12 adult patients with Bonebridge™, 
and after 3 months, the average improvement in sound-field 
PTA
4
 was approximately 25 dB. The corresponding improve-
ment in SRT was on average 25.3 dB, and in SRS in quiet, 
78.8%.59 Four patients with Bonebridge™ presented by 
Barbara et al60 showed an average improvement in PTA
4
 of 36.5 
dB and in SRT of 36.25 dB. Manrique et al61 and Ihler et al62 
calculated the improvement as the difference between preop-
erative unaided PTA-AC (with headphones) and aided PTA in 
sound field. Manrique et al61 had four Bonebridge™ patients 
with conductive or mixed hearing loss and presented a thresh-
old PTA
4
 improvement of 36.9±8.5 dB, and Ihler et al62 had six 
patients with an average PTA
4
 improvement of 34.9±4.5 dB. 
Manrique et al61 also had one SSD patient who presented 
separately where the improvement in PTA
4
 was 17.5 dB. In 
a recent study by Riss et al,63 23 patients with Bonebridge™ 
were evaluated, showing an overall average improvement 
of 28.8±16.1 dB for 0.5–6.0 kHz, using sound field in both 
aided and unaided measurements. The contralateral ear was 
covered with an ear-muff. By comparing preoperative BC 
thresholds with the benefit of the implant, they concluded that 
it is advisable that the preoperative thresholds at all frequen-
cies are better than 45 dB HL (hearing level), as stated by the 
company in the Indications for Use.63 Finally, in a study by 
Plontke et al64 on six subjects, a three-dimensional planning 
tool to prepare for the surgery was presented. Given the size of 
the implant, the Bonebridge™ surgery is deemed to be rather 
difficult, especially if the transducer is to be fitted within the 
mastoid boundaries. The audiometric results in Plontke et al64 
are similar to those in the other studies.
Several of the papers stress that the big size of the 
Bonebridge™ implant can be a challenge, especially in 
Figure 7 Bonebridge™, an active transcutaneous direct-drive bone-conduction 
device.
Note: image provided courtesy of MED-EL.
Figure 6 Bone-conduction implant, an active transcutaneous direct-drive bone-
conduction device.
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patients with a mastoid open cavity and in children who have 
smaller temporal bones. In most studies, it is stated that careful 
 preoperative investigations using computed tomography (CT) 
are needed in order to find a possible site for implantation. 
This site could be retrosigmoidal if not enough space is found 
in the mastoid. A consequence is often that the dura is exposed 
and possibly pushed down to fit the implant. As an example, 
Lassaletta et al65 reports a case of one patient where a retrosig-
moid position was the only option. For a complete insertion, 
a gentle compression of the dura was needed. MED-EL has 
recently released a Lifter system by which the whole implant 
is moved outwards from the skull bone, thus lifting the skin in 
that area in order for the implant to fit the mastoid cavity.
in-the-mouth BCD
A category of BCDs that is neither regarded as direct-drive 
nor skin-drive, is the in-the-mouth device. The vibrations are 
generated by a piezoelectric transducer and are transmitted 
through the teeth to the skull bone. SoundBite™ by Sonitus 
Medical (San Mateo, CA, USA) was developed mainly for SSD 
patients. A microphone is placed behind the ear on the deaf side, 
and the sound is sent wirelessly to an in-the-mouth transducer, 
transmitting vibrations to the upper back teeth. These vibrations 
are transmitted to the skull bone and received by the healthy 
cochlea. In this way, the healthy cochlea hears the sound from 
both sides. The SoundBite™ is illustrated in Figure 8.
Evaluations by Murray et al66,67 showed that the SoundBite™ 
system is safe and effective, with a substantial benefit for SSD 
patients with continual daily use. Gurgel and Shelton68 have 
shown significant APHAB score improvements of, on average, 
21 points.
The most commonly reported problem with the SoundBite™ 
is acoustic feedback.68 Feedback can be minimized with proper 
fitting but still remains for some patients. Another challenge 
with this type of device is that it provides less output at lower 
frequencies due to size and power issues. Syms and Hernandez69 
give an overview of maximum power output in eight BCDs, 
which showed that the SoundBite™ has its highest output and 
gain in the frequency range above 2 kHz. SSD patients mainly 
need high-frequency gain to overcome the head shadow effect; 
hence, for these patients, the SoundBite™ can be a good alter-
native. There might also be distortion and discomfort issues 
when eating. This aspect should not be overlooked, since con-
versation during meals is a daily situation where good hearing 
ability is of great importance.
Maximum power output and bone-
conduction threshold indication
Suggested indication ranges concerning BC thresholds for 
some implantable BCDs, according to companies’ recom-
mendations, are not always supported by published clinical 
data. Therefore, one purpose of this review is to summarize 
audiometric results and try to relate them to a range of rec-
ommended bone-conduction thresholds for use.
In this early phase of implantable BCDs lacking 
enough clinical data, one alternative way is to use the 
objectively measured MPO of these devices, and normal-
hearing threshold data, in order to calculate a guidance to 
an indication range. Zwartenkot et al70 argued that the aided 
PTA should be at least 35 dB HL to get a word recognition 
score of 75%, as proposed by Mueller and Killion71 for AC 
hearing. A summary of such calculations is presented in 
Table 2 and 3, with an estimated indication range based on 
the fact that the aided PTA
4
 should be 30–35 dB HL. The 
authors of this review believe that requiring 35 dB HL as 
aided PTA
4
 is slightly too conservative and that 30 dB HL 
may be sufficient for BCDs, due to 1) that hearing by BC may 
have a steeper loudness growth than AC;72 and 2) patients with 
severe conduction hearing loss may accept some limitation of 
peak levels in their own voice, given that other alternatives 
may have even more severe drawbacks. Therefore it might 
be advisable to have a grey zone of 5 dB (ie, the aided PTA
4
 
should be (at least) in the range of 30–35 dB HL). Assuming 
that the aided PTA
4
 should be at least 30 dB HL, then the max-
imum recommended inclusion level preoperatively in PTA 
for bone conduction (PTAbc) (0.5, 1, 2, and 4 kHz) should be 
32–37 dB HL for the Bonebridge™, 38 dB HL for the BCI, 
24 dB HL for the Sophono®, 39 dB HL for the Baha Divino, 
and 51 dB HL for the Baha Cordelle.
The reason for having two values of maximum PTAbc 
for Bonebridge™ is related to there being two alternative 
methods for the MPO estimation used. One method (Alt 1) 
Figure 8 SoundBite™, an in-the-mouth bone-conduction device with implant for 
tooth attachment and behind-the-ear sound processor.
Note: image provided courtesy of Sonitus Medical.
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is based on skull simulator measurements and reference 
equivalent force threshold levels, same as for BCI, and 
the other method (Alt 2) is experimental and is taken from 
Mertens et al73 (made in situ on patients). Apparently, the 
average dynamic range according to Alt 1 is 5 dB higher 
than the dynamic range according to Alt 2. One reason may 
be that the correction for increased sensitivity in Position 
B relative to Position A is less for Bonebridge™, as it has 
a more rigid bone attachment by using two separated bone 
screws anchored in the outer bone surface. Moreover, one 
can assume that the stronger ear level devices available today 
from Oticon Medical (Ponto Plus Power) and Cochlear Bone 
Anchored Solutions (BP 110 power) should have maximum 
indication range in between those values calculated for 
Divino and Cordelle. Finally, the maximum preoperative 
BC thresholds are indicative and should only be used as 
guidance, given that all other inclusion criteria are met. The 
suggested preoperative BC threshold levels for inclusion are 
also presented in Figure 9.
A summary of the studies discussed in this review is 
displayed in Table 1. Only results that are reasonably com-
parable have been included.
Differences between study protocols
One important note that might affect these comparative 
results is related to how the unaided condition was measured. 
The method of using headphones in the unaided condition 
may, as has been described in the Sophono device section, 
result in a larger gain compared to if sound field measure-
ments are used. The authors believe that the unaided  condition 
should be measured in sound field in the same way as the 
aided condition.
Another issue is how the contralateral ear should be 
managed. The authors’ opinion is that it should be blocked 
by a deep inserted ear-plug to avoid the occlusion effect.74 
Bone-conducted sound will cross over to the contralateral 
cochlea, which is why masking of the contralateral cochlea 
is a non-physiological way of comparing aided and unaided 
condition. Like in all BC applications, the cochlea that is 
dominant (ipsilateral or contralateral) may vary over fre-
quency. Additionally, if masking is used, there is a risk of 
central masking, and also over masking, in cases with large 
ABGs.
Yet another difference is how the speech perception result 
will be affected if including a competing noise or not in the 
setup. For the patient, the most common and demanding 
situation is to perceive speech in a noisy environment. To 
only include speech in quiet does not give any information 
about how the hearing aid functions in the important noisy 
situation for the user.
Caution using ABG when evaluating 
effectiveness of BCDs
There is a tradition among ENT (ear, nose, and throat) 
specialists to discuss whether a device (or surgical treat-
ment) is closing the ABG or not. If a BCD closes the ABG, 
it is generally regarded as an effective device in hearing 
rehabilitation.
The ABG is defined as the difference between AC thresh-
olds, measured by headphones, and BC thresholds, measured 
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Figure 9 Estimated maximum recommended preoperative bone-conduction thresholds, which include a “gray” zone depending on if an aided PTA of at least 30 or 35 dB 
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by bone conductor B71/B81 for one specific ear (left or 
right). By including the aided sound-field thresholds in the 
same audiogram, some argue that the effectiveness of the 
device can be evaluated. For example, if the aided thresholds 
coincide with the bone thresholds, the ABG is closed by 
the device (ie, one could say that the device has fully com-
pensated the conductive loss). However, the authors of this 
review would like to argue that one must be aware that both 
cochleae are stimulated in the aided condition, whereas the 
audiogram presents the hearing ability of an individual ear, 
and it is impossible to know with which cochlea the patient 
is hearing in the aided condition unless the treated cochlea 
is much better than the contralateral cochlea. Depending on 
position, frequency, and individual BC physiology, the two 
cochleae are stimulated with different amplitudes. Based on 
this understanding, the modern BAHAs today, both from 
Cochlear Bone Anchored Solutions and Oticon Medical, 
use a built-in function generator to measure the total BC 
sensitivity (“BC Direct”) when attached to the implant in 
the fitting procedure. This is logical, as the device in the 
aided condition uses the total sensitivity from both cochleae 
and must be fitted to this situation for each given frequency. 
Therefore, the closure or non-closure of the ABG, as defined 
above, should be considered with caution when discussing 
hearing rehabilitation for patients using a BCD. Furthermore, 
a successful hearing rehabilitation depends on many factors, 
and the closure or non-closure of the ABG should in this 
sense be regarded as of minor importance.
Trends in developing BCDs
General trends in hearing devices are to either make them 
more esthetically appealing or to make them as invisible as 
possible. By changing the sound transmission from percu-
taneous to transcutaneous, the visibility of wearing a hear-
ing aid reduces. However, the main reason for developing 
transcutaneous devices is the complications associated with 
skin penetration. These complications have been reduced 
by improvement in the screw and abutment design, and by 
introducing less invasive surgical techniques, but they can 
only be completely eliminated by leaving the skin intact. 
In all the new devices presented in this review paper, the skin 
is intact, and the vibrations are transmitted through the skin 
(passive transcutaneous skin-drive BCDs), directly into the 
bone (active transcutaneous direct-drive BCDs) or via the 
teeth (in-the-mouth BCDs). Hence, the trend is definitely 
towards implantable devices with intact skin.
There are several challenges in developing implant-
able BCDs: 1) they must be powerful enough, 2) they must 
have a good and long-term stable attachment, 3) they must 
be effective and safe for the patient, and 4) they should have 
a solution that is safe for the patient, and preferably also 
safe for the BCD, if a magnetic resonance imaging (MRI) 
investigation is needed.
The first challenge regarding sufficient power is important, 
and also evident from the failures of the Xomed Audiant, and 
to some extent also the conventional BCDs. The conventional 
BCDs are less powerful than the BAHA. The MPO limits the 
output force level of the device, and the patient must have suf-
ficient headroom for ordinary speech levels to avoid distorted 
sound. A reduced MPO also limits the useful gain of the 
device. In active transcutaneous BCDs, the MPO is reduced 
about 10–15 dB by using an inductive link through the skin.47,75 
This is a significant loss, and from the experience with 
BAHA, it can be concluded that such a loss should severely 
limit the use of a link driven device if that loss could not be 
compensated in some way. However, it has been shown that 
the sensitivity increases for BC stimulation positions closer 
to the cochlea. It was found that the acceleration, measured 
by laser Doppler vibrometry on the cochlear promontory 
of cadavers increased by 5–15 dB at frequencies between 
600 Hz and 10 kHz by moving the stimulation position closer 
to the cochlea51–53 as compared with the standard BAHA 
position 55 mm behind the bony ear canal. To compare this 
improved vibration sensitivity to hearing sensitivity (hearing 
thresholds) in patients, two studies were conducted, showing 
that the hearing not only increased in the range from 600 Hz 
to 10 kHz, but also increased at lower frequencies down to 
125 Hz.58,76 For the BCI, in which the transducer also has a 
high-frequency boost around 4.5 kHz, the inductive link loss 
is thus compensated for by moving the stimulation position 
closer to the cochlea, and by the high-frequency boost.58
A second challenge is how to attach and fit the implanted 
transducer casing to the skull bone. A possible solution would 
be to use a titanium screw in the drilled recess of the bone. 
This solution was tested in a cadaver study by Håkansson 
et al51 with good cochlear acceleration as result. However, 
the engagement of inserting screws into deeper areas of the 
temporal bone in humans is hazardous, with a high risk of 
damaging the facial nerve, semi-circular canals, and other 
delicate structures. The mastoid part of the temporal bone is 
built up by air cells, which would also have a negative effect 
of the stability of a screw attachment. In the Bonebridge™, 
the transducer is attached with two osseointegrated screws 
inserted at the surface of the skull bone, one at each side of 
the transducer casing, and thus anchored in the outer compact 
bone, which is safe and similar to what is used in the BAHA. 
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The vibrations of the BC floating mass transducer are then 
transmitted to the bone via the screws, and therefore a small 
clearance between the transducer casing and the bone is 
 created at the bottom of the drilled recess.
In all preclinical investigations, it has been shown that the 
highest sensitivity is achieved if the transducer is attached as 
close as possible to the cochlea. This is one of the reasons 
that the BCI transducer is attached against the flat surface in 
a prepared bottom plane of the recess. It has been proven in 
an animal study that the transmission to the bone is equally 
good with a flat surface attachment as if it had been attached 
with a screw,56 which is also seen by the bone contact 
underneath the transducer57 (ie, the implant was found to be 
osseointegrated). The transducer protrudes 1–2 mm from the 
bone surface and is secured with a titanium wire over the 
casing, as described in Reinfeldt et al.50 It has been discussed 
whether it will be possible to just use compliant resorbable 
sutures instead. Even if the procedure is easy as it is done 
today, there might be future simplifications of this surgery. 
Yet another reason that a flat surface attachment was chosen 
for the BCI is that it is easier to install and also to remove 
the implant. The simplicity of removing the implant can be 
important if, for example, an MRI examination of the head 
is necessary, or in the case of transducer malfunction.
Size might also be an issue, and this was actually yet 
another reason to choose a flat surface contact in the bottom 
of the recess, because it allows an implant of maximum height 
in a limited given space. Not only the height, but also the 
width of the implant, is crucial if the BCI transducer should 
fit most temporal bones. Temporal bones are varying in size 
and might have reduced size, due to chronic infections, 
malformations, or a history of ear surgeries. By studying 
normal temporal bones, it was concluded that for an implant 
of 16 mm in diameter, the maximum depth into the temporal 
bone can be 4 mm to statistically fit 95% of all patients with 
normal temporal bones.77 If the implant diameter is 12 mm, 
the maximum depth into the temporal bone can be 6 mm. 
The BCI transducer size has been based on these results 
(size 14 mm ×12 mm ×7.4 mm), and it fits with good margin 
in all patients included in the Reinfeldt et al77 study. From a 
statistical point of view, and taking the actual implant sizes 
and the allowance of protrusion from the bone surface into 
account, the BCI transducer fits in 95% and the Bonebridge™ 
transducer fits in 40% of normal temporal bones.77
The third challenge concerns the invasiveness of the 
surgery. Less invasive surgery usually implies less risk 
for the patient, and an easier and less costly surgical 
procedure. The deeper the engagement in the bone, the more 
complicated the surgery. This statement might be a reason 
why none of the middle-ear implants have reached the success 
that many believed they would in the 1990s. All surgeries for 
BCDs have been regarded as safe and simple in publications, 
although there could be different grades of the simplicity. 
The BAHA surgery can now be carried out in 10–15 minutes 
under a local anesthesia with the punch technique.45 The 
BCI and the Bonebridge™ surgeries are performed under a 
general anesthesia in most cases. In the Bonebridge™, there 
have been several reports that indicate that the surgery can 
be more difficult because of size issues. For example, in the 
presurgical evaluation, it must be decided whether it fits in the 
mastoid portion of the temporal bone, or whether a retrosig-
moidal position has to be considered. A radiologic evaluation 
is therefore mandatory in this preparatory phase. In the BCI, 
only six patients have been operated on so far; however, in 
none of these has size been an issue, and it is suggested that 
a radiologic preparatory investigation is only needed if the 
patient has either malformations of the temporal bone, or have 
been exposed to previous ear surgeries resulting in an open 
mastoid cavity. Both the procedure for the Bonebridge™ and 
for the BCI can likely be considered to be performed under 
a local anesthesia in the future, if desired.
The fourth and f inal challenge concerns the MRI 
compatibility. A CT, or a low radiation cone beam CT should 
be used as a first choice, but some clinical conditions require 
MRI to obtain the relevant image information. As indicated 
above, the possibility to perform an MRI investigation is 
an important issue in all implantable BCDs as they con-
tain permanent magnet(s) for retention, and in the active 
devices (Bonebridge™ and BCI) there are also soft iron 
components and permanent magnets inside the transducer. 
Even if the implanted parts can be made conditionally MRI 
safe (Bonebridge™ and Sophono® Alpha 1 are certified to 
be conditionally safe up to 1.5 and 3 Tesla, respectively), 
there will be an image artifact in a region near the implant. 
If an MRI absolutely needs to be done with focus on struc-
tures in the skull near the implant, the implant must be 
explanted to eliminate artifacts due to the BCD. Therefore 
it is important to design the implant for such an event. In 
the BCI, prerequisites for an easy explantation has been 
accomplished by not using screws for the attachment. Instead, 
an osseointegrated flat surface is used, and the retention is 
made by an easily removable titanium wire over the implant 
anchored in the outer skull surface. Moreover, regarding 
the BCI, and after studying demagnetization and torque 
of different types of retention magnets, the BCI implant 
is considered to be MRI conditional at a static magnetic 
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field of 1.5 Tesla and with a compression band around 
the skull to fixate the implant.78 However, this is not yet 
approved and requires further verification.78
Conclusion
This paper is a review of existing BCDs on the market or 
in ongoing clinical trials for market approval. They are 
presented under the categories direct-drive, skin-drive, and 
in-the-mouth BCDs. The skin-drive devices are divided into 
conventional and passive transcutaneous devices, while 
the direct-drive devices are divided into percutaneous and 
active transcutaneous devices. Because of soft-tissue chal-
lenges with percutaneous implants, the trend in BCDs is 
towards transcutaneous semi-implantable devices, where 
the skin is kept intact. The four main challenges with 
transcutaneous solutions are related to sufficient power, 
firm and stable implant attachment, surgical invasiveness, 
and MRI compatibility. When comparing the hearing 
improvement with the different devices, the direct-drive 
BCDs, both percutaneous and active transcutaneous, 
provide the best hearing rehabilitation, mainly because of 
the direct stimulation of the bone (no vibrations through 
the skin).
In summary, the authors believe that the existing per-
cutaneous direct-drive BCD (the BAHA) will be retained 
as an important part in hearing rehabilitation, due to 
excellent sound quality and high output power. In the 
future, intact skin solutions will probably replace part of 
the market from the BAHA, and it seems that the active 
transcutaneous direct-drive BCDs (Bonebridge™ and 
BCI) are the most promising systems at present, but more 
extensive clinical studies are needed to specify detailed 
inclusion criteria, and potential benefits and drawbacks 
of these devices.
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